Table S1.

Effect of other factors (than age), on lost to follow-up in the first 36 months after ART initiation (Cox models), for patients <30 years while starting ART

Variables	Number of lost to follow-up	Univariable models		Multivariable models
		HR (95% CI)	P-value	HR (95% CI)	P-value
Gender			<0.0001		<0.0001
Female	4,719	1		1
Male	844	1.22 (1.14–1.32)		1.17 (1.09–1.26)
Year of ART initiation			<0.0001		<0.0001
<2007	1,568	1		1
2007–2010	2,002	1.09 (1.02–1.16)		1.06 (0.99–1.13)
2011 and after	1,993	1.62 (1.52–1.73)		1.68 (1.56–1.81)
Initial clinical stage			<0.0001		<0.0001
A,B/I,II	1,989	1		1
AIDS/III,IV	1,240	1.03 (0.96–1.11)		1.10 (1.02–1.18)
Missing	2,334	1.55 (1.46–1.64)		1.25 (1.17–1.33)
Initial CD4 cell count (cells/µL)			<0.0001		<0.0001
≥350	968	1		1
200–349	1,129	0.71 (0.65–0.77)		0.87 (0.80–0.95)
100–199	970	0.68 (0.63–0.75)		0.88 (0.80–0.96)
50–99	538	0.84 (0.76–0.93)		1.03 (0.92–1.15)
0–49	809	0.93 (0.84–1.02)		1.13 (1.02–1.24)
Missing	1,149	0.81 (0.75–0.89)		0.83 (0.76–0.91)
Initial hemoglobin (g/dL)			<0.0001		<0.0001
≥12	288	1		1
10–12	668	1.08 (0.94–1.24)		1.07 (0.93–1.23)
7.5–10	575	1.19 (1.03–1.37)		1.15 (0.99–1.33)
<7.5	182	1.61 (1.34–1.94)		1.44 (1.19–1.74)
Missing	3,850	1.48 (1.31–1.67)		1.24 (1.10–1.41)
First ART regimen			<0.0001		<0.0001
AZT+3TC/FTC+NVP/EFV	1,316	1		1
D4T+3TC/FTC+NVP/EFV	863	0.85 (0.78–0.92)		0.98 (0.89–1.07)
TDF+3TC/FTC+NVP/EFV	608	1.28 (1.16–1.40)		1.08 (0.97–1.19)
Others/unknown	2,776	1.57 (1.47–1.68)		1.31 (1.21–1.41)
BMI (kg/m2)			<0.0001		<0.0001
18–25	1,235	1		1
<18	572	1.24 (1.12–1.37)		1.18 (1.07–1.31)
≥25	261	0.87 (0.76–0.99)		0.88 (0.77–1.01)
Missing	3,495	2.14 (2.01–2.29)		2.04 (1.89–2.20)
Total number of patients started ART in 2014–2015 and still in care, in the facility			<0.0001		<0.0001
<500	2,673	1		1
500–1000	2,038	0.71 (0.67–0.76)		1.09 (1.01–1.17)
≥1000	852	0.77 (0.72–0.84)		0.67 (0.61–0.73)

Abbreviations: ART, antiretroviral therapy; BMI, body mass index.